HELiXVi connects you with licensed US clinicians for GLP-1 weight loss treatment, including compounded semaglutide and tirzepatide injections and compounded oral tablets. There is no clinic visit: you complete an online medical intake, a clinician reviews your history, and medication ships to your door when clinically appropriate.
In clinical trials, semaglutide produced average body weight reductions of around 15 percent and tirzepatide around 20 percent over roughly 68 to 72 weeks alongside diet and exercise. Individual results vary. Compounded medications are not FDA-approved.
GLP-1 medications carry a boxed warning for thyroid C-cell tumors and are not suitable for everyone. Common side effects include nausea, vomiting, diarrhea, constipation and abdominal pain.
Weight loss prescriptions we supply: [semaglutide injection online](/buy-semaglutide-online), [tirzepatide injection online](/buy-tirzepatide-online), [oral semaglutide tablets](/oral-semaglutide), [tirzepatide tablets](/tirzepatide-tablets), [Ozempic online](/ozempic-online), [Wegovy online](/wegovy-online), [Mounjaro online](/mounjaro-online) and [Zepbound online](/zepbound-online).
HELiXVi prescribes and ships GLP-1 weight loss medication online, with no clinic visit. A licensed clinician reviews your medical history and health goals, then prescribes from FDA-approved injections including Wegovy®, Zepbound®, Mounjaro® and Ozempic®, or from compounded semaglutide and compounded tirzepatide tablets, which are prepared by a licensed pharmacy and are not FDA-approved. Medication ships discreetly each month with ongoing clinician support and dose adjustments. GLP-1 medications are prescribed for adults with a BMI of 30 or above, or 27 or above with a weight-related health condition, alongside diet and exercise. Treatment requires clinician approval and is not guaranteed.
Wegovy® and Zepbound® are FDA-approved specifically for chronic weight management, while Ozempic® and Mounjaro® are approved for type 2 diabetes and prescribed off-label for weight loss. Wegovy® and Ozempic® both contain semaglutide; Zepbound® and Mounjaro® both contain tirzepatide. A clinician decides whether a branded option, compounded semaglutide or compounded tirzepatide is appropriate based on your history, not on preference alone.
| Medication | Active ingredient | FDA-approved for | How it's taken |
|---|---|---|---|
| Wegovy® | Semaglutide | Chronic weight management | Weekly injection |
| Zepbound® | Tirzepatide | Chronic weight management and obstructive sleep apnoea | Weekly injection |
| Ozempic® | Semaglutide | Type 2 diabetes; prescribed off-label for weight loss | Weekly injection |
| Mounjaro® | Tirzepatide | Type 2 diabetes; prescribed off-label for weight loss | Weekly injection |
| Semaglutide tablets | Semaglutide | Compounded; not FDA-approved | Daily dissolvable tablet |
| Tirzepatide tablets | Tirzepatide | Compounded; not FDA-approved | Daily dissolvable tablet |
Compounded medications are prepared by a licensed pharmacy and are not FDA-approved. They are not reviewed by the FDA for safety, efficacy or quality, and are prescribed at the discretion of a licensed clinician based on your individual clinical needs.
Wegovy®, Zepbound®, Mounjaro® and Ozempic® are registered trademarks of their respective manufacturers. HELiXVi is not affiliated with, endorsed by or sponsored by these manufacturers.
Take a 5 minute online assessment. A licensed provider reviews your information, prescribes the right treatment if you qualify, and your medication is shipped free to your door.
GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone that regulates appetite and blood sugar. GLP-1 medications mimic this hormone to reduce hunger, slow digestion, and support fat loss.
Most adults with a BMI of 27 or higher qualify. Our short assessment will confirm your eligibility in minutes.
Common side effects include mild nausea, fatigue, or constipation, especially when starting. Most ease within a few weeks. Your provider will guide you through any side effects.
Many patients notice reduced appetite within the first week and visible weight loss within 4 to 6 weeks. In clinical trials, semaglutide and tirzepatide produced average weight reductions of roughly 15% and 20% of body weight respectively, over roughly 68 to 72 weeks alongside diet and exercise. These are trial figures for the medications, not HELiXVi outcome data, and individual results vary.
No. HELiXVi is a cash pay programme and does not require insurance.
Yes. There are no contracts. You can pause or cancel your treatment at any time from your patient portal.
Compounded GLP-1s are produced in FDA regulated facilities but are not themselves FDA approved. Brand name options like Wegovy® and Zepbound® are FDA approved. Your provider will help you choose the best option for you.
Medication is shipped free in discreet, temperature controlled packaging and is on its way to you within 24 hours of approval.
Nausea, vomiting, diarrhoea, constipation and abdominal pain are the most common side effects, especially when starting treatment or increasing a dose. Serious risks include pancreatitis, gallbladder disease and kidney injury from dehydration. GLP-1 medications carry a boxed warning for thyroid C-cell tumours observed in rodents.
GLP-1 medications are prescribed for adults with a BMI of 30 or above, or 27 or above with a weight-related health condition such as high blood pressure or type 2 diabetes. A licensed clinician reviews your history and decides. Not everyone qualifies.
Wegovy and Ozempic both contain semaglutide but are approved for different uses. Wegovy is FDA-approved for chronic weight management, while Ozempic is approved for type 2 diabetes and prescribed off-label for weight loss. They are also dosed differently.
Weight is commonly regained after stopping GLP-1 treatment. Clinical trial follow-up has shown most participants regain a substantial share of lost weight within a year of discontinuing. Discuss any plan to stop with your clinician rather than stopping treatment abruptly.